Dolzam

Quick links to important sections

Dolzam

Treatment option: Pain, Chronic Pain

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Dolzam

Property Description
Active Ingredient Tramadol Hydrochloride
Form Tablet, Capsule, Solution for injection
Pharmacological Class Opioid analgesic / Central-acting analgesic
General Purpose Management of painful sensations
Origin Synthetic opioid (Cyclohexanol derivative)

The Identity and Classification of Dolzam

Dolzam is a prescription-only medication containing the active component, Tramadol Hydrochloride, which is pharmacologically classified as a centrally acting opioid analgesic. The substance is a synthetic compound structurally related to Cyclohexanol derivative chemicals. This classification is clinically recognized for its utility in pain management across various patient groups. The medication is defined as an opioid agonist.


Composition and Available Forms

The core composition of Dolzam is defined by the single active substance, Tramadol Hydrochloride, often administered as a racemic mixture of two pharmacologically active forms. As a single-ingredient product, it is manufactured in a variety of high-level dosage forms, a feature differentiating it from combination analgesics. These forms include immediate-release and extended-release tablets and capsules, as well as solutions for both oral and parenteral routes. The availability of multiple preparations ensures flexibility for healthcare providers managing a patient's discomfort, particularly when a consistent, long-duration effect is required.


Primary Purpose and Dual-Action Principle

Dolzam's general purpose is to provide relief from painful physical sensations by acting through a distinct dual mechanism. Its action involves both engagement with mu-opioid receptors and the inhibition of reuptake of the natural neurotransmitters norepinephrine and serotonin. This two-pronged action, simultaneously targeting opioid receptors and modulating monoamine activity, is what distinguishes the medication’s efficacy in delivering comprehensive analgesia.

What side effects are possible with Dolzam?

Possible Side Effects and Safety Information

Dolzam (Tramadol Hydrochloride) is a centrally acting opioid, and its safety profile is formally documented by regulatory authorities. The adverse effects are classified by frequency and grouped according to the specific body systems they affect.

Frequency-Classified Adverse Reactions

The most commonly reported effects involve the Central Nervous System (CNS) and Gastrointestinal systems:

  • Very Common (Affects 1 in 10 patients or more): Nausea, dizziness, and somnolence (drowsiness).
  • Common (Affects 1 to 10 in 100 patients): Vomiting, constipation, headache, dry mouth, and sweating (hyperhidrosis).
  • Uncommon (Affects 1 to 10 in 1,000 patients): Effects on cardiovascular regulation (e.g., orthostatic hypotension) and dermatological reactions (e.g., pruritus, urticaria).
  • Rare (Affects 1 to 10 in 10,000 patients): Severe allergic reactions (anaphylaxis), convulsions (seizures), and hallucinations.

Serious Adverse Reactions

Official regulatory documents emphasize the potential for serious, clinically significant events. These include the risk of life-threatening respiratory depression, particularly at the start of treatment or following a dose increase. Other documented serious risks are Serotonin Syndrome, especially when used with other serotonergic agents, and the potential for Seizures, which is increased at higher-than-recommended doses. The risk of dependence, abuse, and misuse is also explicitly noted, particularly with long-term exposure.

Population-Specific Safety Constraints

The medicine is subject to specific regulatory restrictions in certain populations. It is generally contraindicated in children younger than 12 years of age and in adolescents younger than 18 years following tonsillectomy/adenoidectomy. Dose adjustments are often necessary for patients with impaired renal or hepatic function due to the risk of accumulation. Use is generally prohibited in patients with severe respiratory depression or those taking Monoamine Oxidase Inhibitors (MAOIs).

Overdose and Emergency Response

Overdose and when to seek help

Overdose with Dolzam is a serious, life-threatening event that requires immediate emergency intervention. The official regulatory profile is defined by two primary risk patterns.

Documented Manifestations and Severe Outcomes

Overdose manifestations documented in official labeling include profound CNS depression (somnolence, coma, unresponsiveness) and typical opioid signs such as miosis (pinpoint pupils). The most critical outcomes are respiratory depression and respiratory arrest, which can lead to death. Due to the medication's secondary effects, seizures (convulsions) and the potentially fatal Serotonin Syndrome are also documented severe manifestations. Other signs include cardiovascular collapse, vomiting, and cold, clammy skin.

Immediate Emergency Action

Seek immediate medical attention. Patients, caregivers, or bystanders must call emergency services right away if the individual has slowed or shallow breathing, is difficult to wake up, or shows signs of unresponsiveness. The regulatory authorities emphasize that the accidental ingestion of even one dose, especially by a child, can result in a fatal overdose.

Emergency Management and Antidote

The opioid antagonist Naloxone may be administered to partially reverse the life-threatening respiratory depression. However, official labeling cautions that the use of Naloxone may increase the risk of seizures in this context. Supportive treatment, including securing a patent airway and providing assisted ventilation, is essential and takes precedence.

Therapeutic Uses of Dolzam

Quick Facts: Dolzam Therapeutic Use

  • Primary Application: Management of moderate to moderately severe pain.
  • Treatment Goal: Relief for patients where alternative treatments are insufficient or not tolerated.
  • Formulation Use: Extended-release formulations are intended for the management of chronic, around-the-clock pain.

Dolzam is utilized in a medical capacity for the management of pain across a range of severities. Specifically, it is prescribed for pain assessed as moderate to moderately severe in adult patients. Its use is reserved for situations where the severity of the pain is determined to require an opioid analgesic and where other, non-opioid pain treatment options have not provided adequate relief or are unsuitable for the patient.

When administered as an extended-release formulation, the therapeutic benefit is the provision of continuous, around-the-clock pain relief for individuals suffering from chronic pain that persists over an extended duration. This prolonged activity supports consistent pain management.

Eligibility and Restrictions for Use

The eligibility for using Dolzam (Tramadol Hydrochloride) is strictly defined by regulatory documents, outlining populations for whom use is permitted, restricted, or explicitly prohibited.

Populations and Conditions Contraindicated

Use of Dolzam is contraindicated and must be avoided in patients with:

  • Children younger than 12 years of age.
  • Children younger than 18 years of age for post-operative pain after tonsillectomy and/or adenoidectomy.
  • Significant respiratory depression or acute, severe bronchial asthma.
  • Known or suspected gastrointestinal obstruction, including paralytic ileus.
  • Hypersensitivity to tramadol, any component, or other opioids.
  • Concurrent use of Monoamine Oxidase Inhibitors (MAOIs) or within the last 14 days.

Restricted and Conditional Use

Eligibility is limited or conditional for the following groups:

Category Regulatory Limitation
Age Restriction Adolescents 12 to 18 years of age with risk factors (e.g., lung disease) should avoid use. Older adults over 75 years may require caution due to prolonged drug clearance.
Organ Function Severe hepatic impairment and severe renal impairment (CrCl <30 mL/min) are conditions where extended-release formulations are not recommended.
Reproductive Status Pregnancy and breastfeeding are not recommended due to the risk of Neonatal Opioid Withdrawal Syndrome and potential harm to the infant, respectively.

Official Eligibility Statement

Regulatory documents define eligibility through a framework of absolute contraindications—such as age thresholds and respiratory conditions—and conditional use based on the stability of organ function and reproductive status. Eligibility is confirmed only in the absence of these specific prohibitions and restrictions.

What should I know about interactions with other medicines?

Official Interactions Profile

This section details the medicinal product and substance interactions for Dolzam as documented in government regulatory prescribing information.

Formal Restrictions and Timing

  • Monoamine Oxidase Inhibitors (MAOIs): Officially contraindicated for concurrent use. A strict 14-day washout period is required before or after the administration of an MAOI.
  • Alcohol and CNS Depressants: Co-administration with alcohol-containing beverages is prohibited. Concomitant use with other Central Nervous System (CNS) depressants, including certain benzodiazepines and opioids, can significantly enhance the risk of profound sedation and respiratory depression.

Pharmacodynamic (PD) Risk

  • Serotonergic Drugs: Co-administration with drugs that increase serotonin levels (e.g., SSRIs, Triptans) is documented to increase the potential for Serotonin Syndrome.
  • Seizure Risk: The combination of Dolzam with other medicines known to lower the seizure threshold is documented to increase seizure risk.

Pharmacokinetic (PK) and Population Risks

  • CYP Enzyme Modulation: Interactions are defined by the Cytochrome P450 system. CYP2D6 Inhibitors (e.g., Quinidine) are documented to increase parent drug exposure while decreasing the exposure of the active metabolite. Conversely, CYP Inducers (e.g., Carbamazepine) can reduce the analgesic effect.
  • Population-Specific: Regulatory documents identify that CYP2D6 Ultra-Rapid Metabolizers should not use the product due to the documented risk of life-threatening respiratory depression from excessive active metabolite formation.

Mechanism of Action

Dolzam (Tramadol) operates through a dual, complementary mechanism within the Central Nervous System (CNS) to modulate nociceptive signaling pathways, combining receptor activation with neurotransmitter reuptake inhibition.

mu-Opioid Receptor System Modulation

This core mechanism is driven by the drug's metabolite, O-desmethyltramadol (M1), which acts as an agonist at the mu-opioid receptor (MOR). The activation of the MOR initiates a cascade that hyperpolarizes nerve cells, which directly suppresses the release of pro-nociceptive neurotransmitters. This action results in a reduced transmission of nociceptive stimuli along the ascending pathways in the CNS.


Enhancement of Descending Pain Inhibition

The parent drug, Tramadol, engages a separate mechanism by inhibiting the reuptake of the neurotransmitters serotonin (5-HT) and norepinephrine (NE). By increasing the synaptic concentration of these monoamines, the drug enhances the descending pain-inhibitory pathways originating in the brainstem and acting on the spinal cord. This mechanism contributes to an enhanced modulation of nociceptive input.


Mechanistic Constraint by CYP2D6 Activity

The potential activity of the mu-opioid component is functionally constrained by the activity of the CYP2D6 enzyme, which is essential for converting Tramadol into the active M1 metabolite. Reduced activity of this enzyme due to genetic factors leads to a mechanistically diminished level of mu-opioid receptor engagement in the CNS, thus limiting one part of the dual mechanism.

Dosage and Administration Information

Dolzam is officially administered via multiple authorized routes, including oral intake for tablets, capsules, and solution forms, and parenteral routes such as intravenous, intramuscular, or subcutaneous injection. Oral forms may be taken with or without food.

Dosing regimens follow strict regulatory guidelines based on the formulation. Immediate-release (IR) forms are typically administered in single doses of 50 mg to 100 mg every four to six hours, with a maximum total daily dose of 400 mg. Extended-release (ER) forms begin with a typical dose of 100 mg once daily and are titrated upward, generally in 100 mg increments every five days, up to a maximum daily dose of 300 mg. Parenteral solutions are administered slowly or diluted in compatible solutions for infusion.

Specific procedural constraints govern the use of the medicine. Extended-release tablets and capsules must be swallowed whole and must not be crushed, split, or chewed to ensure controlled delivery. Furthermore, the official labeling mandates dose adjustments for certain populations. For adults over 75 years of age or those with severe renal or hepatic impairment, the dosage interval for IR forms is often extended to 12 hours, and extended-release forms are generally not recommended. Treatment is to be limited to the shortest duration necessary, and the dose must be gradually tapered upon discontinuation.

Recent Clinical Evidence

Recent Clinical Evidence

Randomized Controlled Trials (RCTs)

The initial phase of research explored how this agent might be categorized for clinical trials. These studies primarily focused on patients with moderate-to-severe disease presentations.

  • Core Symptom Analysis: Studies examined whether the agent affected the core symptoms of the condition and looked for evidence of differences in flare-up rates. The primary endpoint for many trials was a composite score evaluating disease activity at the six-month mark.
  • Quality of Life (QoL) and Pain: Key studies investigated whether the agent was associated with patient-reported QoL and evaluated findings related to pain associated with the disease. Findings related to patient QoL were mixed across different trial populations.
  • Long-Term Follow-up: Long-term extension studies were designed to evaluate findings at the two-year mark. These studies provided limited information on whether the initial findings were maintained after the main trial concluded.

Combination and Comparative Studies

Research has investigated whether the combination of treatments was associated with measured outcomes in individuals with chronic presentations. These trials primarily compared the agent used alone versus the agent used in combination with an established therapeutic compound.

  • Efficacy Endpoints: Studies evaluated whether the two treatments used together resulted in a different outcome compared to monotherapy. Studies evaluated differences in response endpoints between the combination group and the monotherapy group.
  • Head-to-Head Research: Head-to-head research was conducted to compare this agent against alternative treatment options over a one-year period. The research assessed the safety profile in adults in these studies, and reports of specific mild adverse events were documented.
  • Drug-Drug Interactions: Potential for interactions with other medications was evaluated in the research. Studies assessed the effect on metabolism and clearance when the agent was co-administered with select common pharmaceuticals.

Frequently Asked Questions (FAQ)

Common questions about Dolzam (FAQ)

Q: How quickly should I expect to feel the effects of Dolzam?

A: According to official product information for the immediate-release form, patients may expect pain relief, or analgesia, to begin about one hour after administration. The peak pain-relieving effect is typically observed within approximately two to three hours.


Q: How long does one dose of Dolzam typically stay in your system?

A: Regulatory information indicates that the drug and its active form have a half-life—the time it takes for half the drug to be eliminated—of approximately six to seven hours. The body removes Dolzam and its breakdown products primarily through the kidneys.


Q: What's the difference between Dolzam and the generic version?

A: Dolzam is the brand name for the active ingredient, Tramadol Hydrochloride. Generic forms are considered therapeutically equivalent, meaning they contain the same active ingredient, strength, and dosage form. Differences exist only in the inactive ingredients, such as coloring, flavoring, or non-active fillers.


Q: Is it safe to drink coffee while on a Dolzam regimen?

A: The official product information does not list any formal restrictions or contraindications regarding caffeine intake. However, Dolzam is known to cause CNS effects like dizziness and somnolence (drowsiness). Patients should be aware of how their body reacts to the combination of stimulants and medications that cause sedation.


Q: Is Dolzam safe for teenagers?

A: Official regulatory warnings state that Dolzam is contraindicated (must not be used) in children younger than 12 years old. Its use is also discouraged or should be avoided in adolescents (ages 12 to 18) with certain risk factors like severe lung disease, or following specific surgeries like tonsillectomy or adenoidectomy.


Q: What happens if you miss a dose of Dolzam?

A: If a dose is missed, patients should consult the specific instructions on the product labeling or contact their pharmacist, as dosing intervals must be maintained to ensure safety. Regulatory warnings state that a double dose should not be taken to make up for a missed one.


Q: How long do most people stay on Dolzam treatment?

A: The principle for all opioid analgesics, including Dolzam, is to use the medication for the shortest duration necessary for pain management, as assessed by a healthcare provider. For long-term use, regulatory documents require the continued need for the medication to be regularly assessed.


Q: Is it normal to feel a metallic taste after starting Dolzam?

A: A metallic taste is not typically listed among the very common or common side effects in major clinical trials. If this occurs, it is an effect that should be discussed with a healthcare provider.


Q: What are the signs that Dolzam is actually working?

A: The primary indicator that the medication is working is a reduction or relief in the painful sensations it was prescribed to address. The drug's mechanism is designed to suppress the transmission of pain signals in the central nervous system, resulting in the desired analgesic effect.


Q: Can Dolzam affect your sleep pattern?

A: Yes, regulatory documents indicate that Dolzam can affect sleep. While drowsiness (somnolence) is a very common side effect, post-marketing reports have also included effects on sleep, such as sleep disturbance, insomnia, or having vivid dreams or nightmares.


Q: Can men and women use Dolzam for the same conditions?

A: Yes, the official indications for Dolzam are the same for both men and women. Studies examining drug concentrations in the body have shown only small, clinically insignificant differences between sexes, and these do not affect the approved uses.


Q: Does Dolzam cause weight gain or loss?

A: Weight changes are not listed as common side effects. However, regulatory documents have noted metabolic adverse effects, including changes in appetite. Some post-marketing reports have included both weight decrease (anorexia) and weight gain.


Q: Can you take cold and flu medicine while I'm on Dolzam?

A: Caution is advised because many cold and flu products can interact with Dolzam. Combining Dolzam with ingredients that depress the Central Nervous System (CNS) or increase serotonin levels can significantly raise the risk of serious side effects. Due to the complexity of these interactions, it is advisable that patients confirm the safety of all ingredients with a healthcare professional or pharmacist.


Q: Is it common to have vivid dreams when starting Dolzam?

A: Vivid dreams, nightmares, or unusual dreams have been noted in official post-marketing adverse event reports. While they are a recognized effect, they are not listed as one of the very common side effects experienced by most patients in clinical trials.


Q: Does the efficacy of Dolzam vary depending on the patient's age?

A: Yes, efficacy can be influenced by age. The drug is contraindicated for young children due to safety risks. For older adults (over 75 years), clearance of the drug from the body is generally slower, and the official label notes that dosage modification is often required.


Q: Why is my prescription for Dolzam a different color this time?

A: A change in the tablet's color usually means you have received the same active ingredient, Tramadol Hydrochloride, but from a different pharmaceutical manufacturer. Manufacturers use different, non-active ingredients, such as coloring agents or binders, which results in a different appearance while maintaining the same medical efficacy.


Q: Can I stop taking Dolzam abruptly if I feel better?

A: Official warnings state that abrupt discontinuation of Dolzam is generally avoided for patients who may have developed physical dependence. The regulatory label mandates that the dose must be gradually tapered upon discontinuation to minimize the risk of withdrawal symptoms, which should occur under medical supervision.


Q: Does Dolzam show up on standard drug tests?

A: As a controlled substance (Schedule IV in the US), Dolzam can be detected. While it is not typically included in standard five- or ten-panel drug screens, it can be detected with a specific screening for synthetic opioids or through a specialized, extended drug panel.


Q: Do people take Dolzam for anxiety or pain?

A: Official regulatory documents specify that Dolzam is indicated only for the management of pain. It is not approved or indicated for the treatment of anxiety or other mental health conditions.


Q: Are there any supplements that should definitely be avoided while taking Dolzam?

A: Yes, supplements that increase serotonin levels should be avoided, as this can lead to a serious condition called Serotonin Syndrome when combined with Dolzam. A known example is St. John’s Wort, an herbal supplement that affects the serotonin system.


Q: Does Dolzam have any known effects on mood?

A: Yes, official regulatory documents list adverse reactions categorized under psychiatric disorders. These can include mood changes, anxiety, confusion, and in rare cases, hallucinations.


Q: What's the typical duration of the benefits from a single dose of Dolzam?

A: The duration of pain relief from the immediate-release form is usually aligned with its dosing interval, which is typically four to six hours. This is the timeframe during which the drug is providing its maximum analgesic effect.


Q: Are there any restrictions on operating machinery while taking Dolzam?

A: Official warnings state that due to the potential for dizziness and somnolence (drowsiness), patients are generally advised to avoid driving, operating heavy machinery, or engaging in hazardous tasks.

How should Dolzam be stored and disposed of?

Storage and Disposal of Dolzam

Official regulatory guidelines strictly define how Dolzam (Tramadol Hydrochloride) must be stored and discarded.


Storage Conditions

Dolzam must be kept at 20 C to 25 C (68 F to 77 F), which aligns with Controlled Room Temperature. The container must be kept tightly closed and protected from both light and moisture to maintain product stability. Due to the risk of fatal accidental ingestion, the medicine must be stored out of the sight and reach of children at all times, as mandated for all opioid analgesics.


Disposal Instructions

Unused or expired Dolzam should be returned through a community-based drug take-back program. If a take-back option is unavailable, the U.S. FDA instructs that this high-risk opioid be immediately flushed down the sink or toilet to prevent accidental exposure and harm. All disposal must adhere to local environmental requirements for medicinal waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Dolzam found in:

A-Z Index: